What is Moderna's current stock price?

Moderna shares are trading near $57 after a 9% gain on Tuesday.

Has Moderna outperformed Pfizer and Novavax?

Yes, Moderna's 94% YTD gain is the best among major vaccine stocks, outperforming Pfizer (PFE) and Novavax.

What caused Moderna's stock to rise today?

No specific catalyst was cited, but the strong YTD performance may reflect investor confidence in mRNA technology.

Moderna Surges 94% in 2026, Outpacing Pfizer and Novavax

Moderna (MRNA) continues its rally, up 94% year-to-date in 2026, easily outperforming vaccine peers like Pfizer and Novavax. Shares rose 9% today to near $57.

June 16, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

moderna ytd return

94%

moderna daily gain

moderna current price

$57

Moderna Surges 94% in 2026, Outpacing Pfizer and Novavax

Moderna (NASDAQ:MRNA) stock is jumping again, up 9% in Tuesday afternoon trading to around $57. This extends a remarkable 2026 run for the mRNA pioneer, pushing the stock to +94% year-to-date (YTD) — easily the best performance among major vaccine stocks.

Moderna vs. Peers

While exact figures for Pfizer (NYSE:PFE) and Novavax were not provided, Moderna's 94% gain clearly leads the cohort. This outperformance comes amid renewed investor interest in the vaccine sector.

Reasons for the Surge

No specific catalyst was cited for today's move, but the strong YTD performance may reflect confidence in mRNA technology and Moderna's pipeline expansion into other therapeutic areas.

Broader Context

Moderna's rally follows a period of volatility in the vaccine space after the pandemic peak. The stock appears to be regaining momentum.

What This Means for Investors

Moderna's 94% gain in 2026 is eye-catching, but past performance does not guarantee future results. Investors should monitor upcoming earnings and regulatory developments.

Frequently Asked Questions

Moderna (MRNA) stock has gained 94% year-to-date in 2026 as of the article.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.